AxoGen, Inc. (AXGN) FinancialsAXGNAxoGen, Inc.

Evaluating the bottom line, AxoGen, Inc. maintains a gross margin of 72.67%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3.09%, while the net margin is -2.17%. These profitability ratios, combined with a Return on Equity (ROE) of -18.21%, provide a clear picture of how effectively AXGN converts its operational activities into shareholder value.

In the context of the broader market, AXGN competes directly with industry leaders such as BFLY and INSP. With a market capitalization of $2.18B, it holds a significant position in the sector. When comparing efficiency, AXGN's gross margin of 72.67% stands against BFLY's 71.41% and INSP's 85.48%. Such benchmarking helps identify whether AxoGen, Inc. is trading at a premium or discount relative to its financial performance.

AxoGen has shown fluctuating financial performance with total revenue increasing from $49.4 million in Q4 2024 to $69.7 million in Q2 2026. However, net income has been negative for several quarters, with the latest at -$1.516 million in Q2 2026. The gross margin remains strong at 72.67%.